An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

A 47-year-old man presented with witnessed out-of-hospital cardiac arrest at his wedding and anterior ST-elevation myocardial infarction. Initial blood pressure was 90/60 mmHg with pulse of 115 beats/minute...

Michele Pighi provides his take on the National Cardiovascular LAAO Registry that analyzed data from 51,333 patients who underwent LAAO procedures with the WATCHMAN device between 2016-2019, as part of the College's NCDR registries.

Mirvat Alasnag provides her take on the outcomes of small annuli sub-study from the FRANCE-TAVI Registry which included 1,195 patients. This trial was presented by Walid Ben-Ali at TCT 2022.

In this case report, we examine an advanced technique for renal denervation (RDN)—ultrasound energy—employed to manage severe hypertension in patients with complex medical histories.

At TCT Connect 2020, Nils Johnson presented the results of the DEFINE-FLOW study. Carlos Collet provides a summary of the key messages.

Edoardo Zancanaro provides his take on the ENBALV trial presented by Chisato Izumi at AHA 2024 in Chicago.

Elad Asher provides his take on the ASSURE DES trial presented by Jung-Min Ahn at the ESC Congress 2024 in London.

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Alex Sticchi provides his take on the PRE18FFIR trial: Prediction of recurrent events with 18F-Sodium Fluoride to identify ruptured and high-risk coronary artery plaques in patients with myocardial infarction.

An 80-year-old man underwent percutaneous coronary intervention with a bare-metal stent for severe stenosis at proximal left anterior descending coronary artery 13 years ago. In-stent restenosis was treated by a drug-eluting stent 1 year later...

Elad Asher provides his take on the PEERLESS trial presented by Wissam A. Jaber at TCT 2024 in Washington.

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Nicola Ryan provides a PICOT analysis of PACMAN AMI: a double-blind, placebo-controlled, randomized trial presented at ACC 2022 and simultaneously published in JAMA.

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan provides her take on the ECLIPSE trial presented by Ajay J. Kirtane at TCT 2024 in Washington.